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REVERT is the first randomised 
controlled trial to investigate the use 
of a modified Valsalva manoeuvre to 
treat patients presenting with SVT in 
the emergency department. 
METHODS: 
RESULTS:  
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BACKGROUND: The Valsalva manoeuvre is an internationally recommended physical emergency 
treatment for supraventricular tachycardia (SVT), an abnormal fast heart rhythm. However in 
normal practice, the manoeuvre only works in 5–20% of cases and intravenous treatment with 
adenosine is required. This drug causes a pause in heart activity which patients often find very 
distressing. A simple posture modification to the Valsalva manoeuvre could improve its 
effectiveness and we carried out a randomised controlled trial to assess whether it could 
increase the rate of cardioversion and reduce use of adenosine.  
We enrolled 433 participants in 10 
emergency departments in the 
South- West. 5 duplicate cases were 
excluded. In an intention-to-treat 
analysis, 37 (17%) of 214 participants 
REVERT Trial Protocol 
*Central independent 1:1 randomisation stratified by centre.  
This study is registered with Current Controlled Trials (ISRCTN67937027). 
Inclusion Criteria 
Adults 
Stable SVT (narrow 
complex, regular) 
Exclusion Criteria 
Unstable patients 
Atrial flutter/fibrillation 
Broad complex tachy 
VM or modification 
contraindicated 
Prior study participant 
 
Patient arrives in ED with SVT 
Patient Screened 
Patient Randomised* 
Modified Valsalva (Max X2) Standard Valsalva (Max X2) 
Primary outcome 
Return to sinus rhythm at 1 minute, determined by ECG and confirmed by 
an investigator blind to treatment allocation 
CONCLUSIONS: In patients with 
supraventricular tachycardia, a 
modified Valsalva manoeuvre with 
leg elevation and supine positioning 
at the end of the strain significantly 
increases cardioversion to sinus 
rhythm, reduces use of adenosine 
and should be considered as a 
routine first line treatment 
assigned to standard Valsalva manoeuvre achieved sinus 
rhythm compared with 93 (43%) of 214 in the modified 
Valsalva manoeuvre group (adjusted odds ratio 3·7 (95% 
CI 2·3–5·8; p<0·0001). Adenosine use was also significantly 
reduced in the modified group. We recorded no serious 
adverse events. Groups were well matched and achieved 
the same strains. 
Number of modified Valsalvas needed to 
prevent treatment with adenosine=3 
REVERT Trial Protocol* 
*REVERT Protocol paper:  BMJ Open 2014;4:e004525. doi:10.1136/bmjopen-2013-004525 
Patient arrives with SVT 
Patient Screened 
Patient Randomised 
Modified Valsalva (Max X2) Standard Valsalva (Max X2) 
Exclusion Criteria 
• Unstable patients 
• Atrial flutter/fibrillation 
• Broad complex tachy 
• VM contraindicated 
• If modification could 
cause harm 
• Prior study participant 
 
Inclusion Criteria 
• Adults 
• Stable SVT (narrow 
complex, regular) 
